Dr. Chi Discusses the LATITUDE Study in Metastatic Prostate Cancer

Kim Chi, MD
Published: Monday, Jul 24, 2017



Kim Chi, MD, associate director of clinical research, Vancouver Prostate Centre, professor, Department of Medicine, University of British Columbia, discusses the LATITUDE study in metastatic prostate cancer.

This was a randomized phase III, double-blind, placebo-controlled trial that enrolled approximately 1200 men with hormone-naïve metastatic prostate cancer. Patients were randomized to receive either standard therapy with androgen-deprivation therapy (ADT) with placebo versus ADT with abiraterone acetate (Zytiga) and prednisone at 5 mg per day.

Results showed an overall survival advantage in patients who received ADT plus abiraterone acetate and prednisone, says Chi.
 
SELECTED
LANGUAGE


Kim Chi, MD, associate director of clinical research, Vancouver Prostate Centre, professor, Department of Medicine, University of British Columbia, discusses the LATITUDE study in metastatic prostate cancer.

This was a randomized phase III, double-blind, placebo-controlled trial that enrolled approximately 1200 men with hormone-naïve metastatic prostate cancer. Patients were randomized to receive either standard therapy with androgen-deprivation therapy (ADT) with placebo versus ADT with abiraterone acetate (Zytiga) and prednisone at 5 mg per day.

Results showed an overall survival advantage in patients who received ADT plus abiraterone acetate and prednisone, says Chi.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x